Liu Chuanming, Chen Ke, Xu Zijian, Wang Lianshun, Zhu Yinhua, Yu Zhengquan, Li Tong, Huang Jiaqiang
Key Laboratory of Precision Nutrition and Food Quality, Department of Nutrition and Health, China Agricultural University, Beijing 100193, China.
Beijing Laboratory of Food Quality and Safety, Department of Nutrition and Health, China Agricultural University, Beijing 100193, China.
Nutrients. 2025 Jul 30;17(15):2484. doi: 10.3390/nu17152484.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is one of the most prevalent chronic diseases in the world, lacking specific pharmacological interventions or well-established treatments. MASLD involves intricate pathological mechanisms characterized by oxidative stress and robust inflammatory responses. Selenium, an essential trace element, plays a critical role in antioxidation, regulation of inflammation, anticancer activity, and so on. Recent studies have reported that supplementation with selenium could alleviate MASLD and associated hepatic disorders, while excessive consumption may result in insulin resistance or even selenosis. Therefore, supranutritional selenium supplementation can be more suitable for the therapy and prevention of MASLD. This paper comprehensively reviews research about selenium and MASLD to highlight the potential applications and risks of supranutritional selenium supplementation in MASLD, following three steps: conducting a search, reviewing research articles and reviews, and discussing results. The keywords for the search include but are not limited to selenium, MASLD, supranutritional, hepatic diseases, selenoproteions, and selenium nanoparticles (SeNPs). We have reached the following conclusions: supranutritional selenium supplementation exhibits promising potential as a strategy to treat MASLD, but there are still some risks, depending on the dose and form of selenium; evaluating MASLD severity and selenium nutritional status accurately, as well as supplementing with superior forms of selenium (e.g., organic selenium and SeNPs), can further ensure the safety and efficacy of selenium supplementation. However, relationships between selenium homeostasis disorders and the occurrence and development of MASLD have not been fully elucidated. Methods for comprehensively assessing selenium status and mechanisms of selenosis require further investigation and research.
代谢功能障碍相关脂肪性肝病（MASLD）是世界上最常见的慢性病之一，缺乏特异性药物干预或成熟的治疗方法。MASLD涉及复杂的病理机制，其特征为氧化应激和强烈的炎症反应。硒作为一种必需微量元素，在抗氧化、炎症调节、抗癌活性等方面发挥着关键作用。最近的研究报道，补充硒可以缓解MASLD及相关肝脏疾病，而过量摄入可能导致胰岛素抵抗甚至硒中毒。因此，超营养剂量补充硒可能更适合MASLD的治疗和预防。本文全面综述了关于硒与MASLD的研究，以突出超营养剂量补充硒在MASLD中的潜在应用和风险，分三步进行：检索、综述研究文章和综述、讨论结果。检索关键词包括但不限于硒、MASLD、超营养、肝脏疾病、硒蛋白和硒纳米颗粒（SeNPs）。我们得出以下结论：超营养剂量补充硒作为治疗MASLD的策略具有广阔前景，但仍存在一些风险，这取决于硒的剂量和形式；准确评估MASLD严重程度和硒营养状况，以及补充优质形式的硒（如有机硒和SeNPs），可以进一步确保补硒的安全性和有效性。然而，硒稳态紊乱与MASLD发生发展之间的关系尚未完全阐明。全面评估硒状态的方法和硒中毒机制需要进一步研究探索。
